Restless legs syndrome: Update on pathogenesis

Current Opinion in Pulmonary Medicine

Volumn 19, Issue 6, 2013, Pages 594-600

  Dauvilliers, Yves ^a,b   Winkelmann, Juliane ^c,d  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b INSERM U1061   (France)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d STANFORD UNIVERSITY   (United States)

Author keywords

dopamine; genetic; iron; periodic leg movements; restless legs syndrome

Indexed keywords

DOPAMINE 2 RECEPTOR; FERRITIN; GLUTAMIC ACID; IRON; TYROSINE 3 MONOOXYGENASE;

BRAIN DISEASE; BRAIN LEVEL; CEREBROVASCULAR DISEASE; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; IRON DEFICIENCY; IRON METABOLISM; IRON STORAGE; IRON TRANSPORT; MICROVASCULATURE; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PROTEIN CEREBROSPINAL FLUID LEVEL; PUTAMEN; RESTLESS LEGS SYNDROME; REVIEW; SUBSTANTIA NIGRA;

DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HOMEODOMAIN PROTEINS; HUMANS; IRON; MALE; NEOPLASM PROTEINS; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; TRANSCRIPTION FACTORS;

EID: 84885182447     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328365ab07     Document Type: Review

References (50)

1. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4:101-119.
2. Trenkwalder C, Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol 2010; 6:337-346.
3. Zucconi M, Ferri R, Allen R, et al. The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med 2006; 7:175-183.
4. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005; 13: 1286-1292.
5. Tison F, Crochard A, Lé ger D, et al. Epidemiology of restless legs syndrome in French adults. Neurology 2005; 65:239-246.
6. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003; 4:121-132.
7. Winkelmann J, Wetter TC, Collado-Seidel V, et al. Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep 2000; 23:597-602.
8. Whittom S, Dauvilliers Y, Pennestri MH, et al. Age-at-onset in restless legs syndrome\: A clinical and polysomnographic study. Sleep Med 2007; 9:54-59.
9. Earley CJ, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000; 54:1698-1700.
10. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4:101-119.
11. Ondo WG, He Y, Rajasekaran S, Le WD. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats\: A possible model for restless legs syndrome. Mov Disord 2000; 15:154-158.
12. Xiong L, Jang K, Montplaisir J, et al. Canadian restless legs syndrome twin study. Neurology 2007; 68:1631-1633.
13. Xiong L, Montplaisir J, Desautels A, et al. Family study of restless legs syndrome in Quebec, Canada: clinical characterization of 671 familial cases. Arch Neurol 2010; 67:617-622.
14. Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007; 39:1000-1006.
15. Winkelmann J, Czamara D, Schormair B, et al. Genomewide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genet 2011; 7:e1002171.
16. Stefansson H, Rye D, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007; 357:639-647.
17. Vilarino-Gü ell C, Farrer MJ, Lin SC. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2008; 358:425-427.
18. Xiong L, Catoire H, Dion P, et al. MEIS1 intronic risk haplotype associated with restless legs syndrome affects its mRNA and protein expression levels. Hum Mol Genet 2009; 18:1065-1074.
19. Catoire H, Dion PA, Xiong L, et al. Restless legs syndrome-associated MEIS1 risk variant influences iron homeostasis. Ann Neurol 2011; 70:170-175.
20. Oexle K, Schormair B, Ried JS, et al. Dilution of candidates. The case of ironrelated genes in restless legs syndrome. Eur J HumGenet 2013; 21:410-414.
21. Bonati MT, Ferini-Strambi L, Aridon P, et al. Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain 2003; 126:1485-1492.
22. Desautels A, Turecki G, Montplaisir J, et al. Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet 2001; 69:126670.
23. Desautels A, Turecki G, Montplaisir J, et al. Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity. Arch Neurol 2005; 62:591-596.
24. Kemlink D, Polo O, Montagna P, et al. Family-based association study of the restless legs syndrome loci 2 and 3 in a European population. Mov Disord 2007; 22:207-212.
25. Levchenko A, Montplaisir JY, Asselin G, et al. Autosomal-dominant locus for Restless Legs Syndrome in French-Canadians on chromosome 16p12.1. Mov Disord 2009; 24:40-50.
26. Winkelmann J, Lichtner P, Schormair B, et al. Variants in the neuronal nitric oxide synthase (nNOS, NOS1) gene are associated with restless legs syndrome. Mov Disord 2008; 23:350-358.
27. Chen S, Ondo WG, Rao S, et al. Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet 2004; 74:876-885.
28. Liebetanz KM, Winkelmann J, Trenkwalder C, et al. RLS3: fine-mapping of an autosomal dominant locus in a family with intrafamilial heterogeneity. Neurology 2006; 67:320-321.
29. Schormair B, Kemlink D, Roeske D, et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet 2008; 40:946-948.
30. Schormair B, Plag J, Kaffe M, et al. MEIS1 and BTBD9: genetic association with restless leg syndrome in end stage renal disease. J Med Genet 2011; 48:462-466.
31. Clemens S, Hochman S. Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D3 receptor knock-out mice. J Neurosci 2004; 24:11337-11345.
32. Zhao H, Zhu W, Pan T, et al. Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation. J Neurosci Res 2007; 85:1065-1076.
33. Bucher SF, Seelos KC, Oertel WH, et al. Cerebral generators involved in the pathogenesis of the restless legs syndrome. Ann Neurol 1997; 41:639-645.
34. Earley CJ, Allen RP, Connor JR, et al. The dopaminergic neurons of the A11 system in RLS autopsy brains appear normal. Sleep Med 2009; 10:1155-1157.
35. Freeman A, Pranski E, Miller RD, et al. Sleep fragmentation and motor restlessness in a Drosophila model of restless legs syndrome. Curr Biol 2012; 22:1142-1148.
36. DeAndrade MP, Johnson RL Jr, Unger EL, et al. Motor restlessness, sleep disturbances, thermal sensory alterations and elevated serum iron levels in Btbd9 mutant mice. Hum Mol Genet 2012; 21:3984-3992.
37. Allen RP, Barker PB, Wehrl F, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001; 56:263-265.
38. Earley CJ, Barker P, Horska A, Allen RP. MRI-determined regional brain iron concentrations in early-and late-onset restless legs syndrome. Sleep Med 2006; 7:458-461.
39. Connor JR, Wang XS, Patton SM, et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 2004; 62:1563-1567.
40. Connor JR, Ponnuru P, Wang XS, et al. Profile of altered brain iron acquisition in restless legs syndrome. Brain 2011; 134:959-968.
41. Earley CJ, Kuwabara H, Wong DF, et al. The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome. Sleep 2011; 34:341-347.
42. Allen RP, Connor JR, Hyland K, Earley CJ. Abnormally increased CSF 3-orthomethyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. Sleep Med 2009; 10:123-128.
43. Connor JR, Wang XS, Allen RP, et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain 2009; 132: 2403-2412.
44. Rizzo G, Tonon C, Testa C, et al. Abnormal medial thalamic metabolism in patients with idiopathic restless legs syndrome. Brain 2012; 135:3712-3720.
45. Allen RP, Barker PB, Horská A, Earley CJ. Thalamic glutamate/glutamine in restless legs syndrome: increased and related to disturbed sleep. Neurology 2013; 80:2028-2034.
46. Walters AS, Rye DB. Review of the relationship of restless legs syndrome and periodic limb movements in sleep to hypertension, heart disease, and stroke. Sleep 2009; 32:589-597.
47. Winkelman JW, Shahar E, Sharief I, Gottlieb DJ. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 2008; 70:35-42.
48. Innes KE, Selfe TK, Agarwal P. Restless legs syndrome and conditions associated with metabolic dysregulation, sympathoadrenal dysfunction, and cardiovascular disease risk\: A systematic review. Sleep Med Rev 2012; 16:309-339.
49. Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force b. The European Federation of Neurological Societies. The European Neurological Society and the European Sleep Research Society. Eur J Neurol 2012; 19:1385-1396.
50. Bayard S, LangenierMC, Dauvilliers Y. Effect of psychostimulants on impulsivity and risk taking in narcolepsy with cataplexy. Sleep 2013; 36:1335-1340.